CEO Update: April 2020
InSitu Biologics has continued to make great strides over the past few months. We have successfully submitted our Pre-IND application to the FDA, as well as applied for a National Institute of Health federal grant to support our development costs. During this time of uncertainty caused by the COVID-19 situation, our team remains healthy, grateful for your continued support, and committed to providing a better solution for patients with post-operative pain.
For additional information regarding our progress, please take some time to read our company update.